How Adherium is Revolutionising Respiratory Health Care

In this video, Unknown Host sits down with Dawn Bitz, CEO of Adherium, to explore the innovative approaches the company is using to tackle respiratory health issues. Adherium, a leader in digital health technology, has developed smart-adherence jackets that track medication usage for patients with respiratory diseases like asthma and emphysema. These jackets are designed to improve medication compliance through sophisticated sensors, ultimately aiming to reduce hospitalisation rates and healthcare costs. Dawn shares insights from a recent partnership with Intermountain Health, showcasing impressive data that underlines the effectiveness of their technology in improving patient outcomes. With the goal of expanding their remote patient monitoring revenue model and targeting 10,000 RPM patients by 2026, Adherium’s story is one of innovation and potential growth in the healthcare sector. Timestamps: 00:00 - Introduction 00:45 - Overview of Adherium 02:15 - The impact of respiratory diseases 04:30 - Key innovations in medication usage 06:00 - Partnership with Intermountain Health 08:15 - Revenue models and future targets 10:00 - Scaling operations and targets for 2026 12:00 - Conclusion If you're interested in understanding how technology is changing health care, make sure you subscribe and turn on notifications for more insights from leaders in the small-cap sector. ⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed. 📌 Articles: https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us 🔎 More on Adherium: https://smallcaps.com.au/stocks/asx-adr/ ⸻ Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies. 🌐 WEBSITE https://smallcaps.com.au/ 🎧 PODCAST https://smallcaps.com.au/podcast/ 📱 SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/ 📬 NEWSLETTER https://smallcaps.com.au/subscribe/